Condition
Multisystem Inflammatory Syndrome in Children (MIS-C)
Total Trials
6
Recruiting
2
Active
3
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
1Total
P 3 (1)
Trial Status
Completed2
Recruiting2
Active Not Recruiting1
Enrolling By Invitation1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT04278404Recruiting
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT07659847RecruitingPrimary
Cardiovascular Assessment 5 Years After MIS-C
NCT05287412Active Not RecruitingPrimary
Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children
NCT07126028Enrolling By InvitationPrimary
Quality of Life in Children After Multisystem Inflammatory Syndrome in Children
NCT04640038Phase 3Completed
Contrast Enhanced Ultrasound in COVID-19
NCT04588363Completed
COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
Showing all 6 trials